Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ANIXA BIOSCIENCES INC (ANIX : NSDQ)
 
 • Company Description   
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.13 Daily Weekly Monthly
20 Day Moving Average: 302,817 shares
Shares Outstanding: 32.92 (millions)
Market Capitalization: $135.95 (millions)
Beta: 0.66
52 Week High: $4.98
52 Week Low: $2.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 26.30% 24.00%
12 Week 38.59% 29.46%
Year To Date 78.02% 53.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3150 Almaden Expressway Suite 250
-
San Jose,CA 95118
USA
ph: 408-708-9808
fax: 631-549-5974
mcatelani@anixa.com http://www.anixa.com
 
 • General Corporate Information   
Officers
Amit Kumar - Chief Executive Officer and Chairman
Michael J. Catelani - President; Chief Operating Officer and Chief Finan
Lewis H. Titterton, Jr - Director
Arnold Baskies - Director
Emily Gottschalk - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03528H109
SIC: 2834
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: 07/01/25
Next Expected EPS Date: 01/09/26
Share - Related Items
Shares Outstanding: 32.92
Most Recent Split Date: 6.00 (0.04:1)
Beta: 0.66
Market Capitalization: $135.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 01/09/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 8.63
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.00%
vs. Previous Quarter: 22.22%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
10/31/25 - -
07/31/25 - -67.45
04/30/25 - -68.17
ROA
10/31/25 - -
07/31/25 - -59.18
04/30/25 - -60.38
Current Ratio
10/31/25 - -
07/31/25 - 8.45
04/30/25 - 8.89
Quick Ratio
10/31/25 - -
07/31/25 - 8.45
04/30/25 - 8.89
Operating Margin
10/31/25 - -
07/31/25 - -
04/30/25 - -
Net Margin
10/31/25 - -
07/31/25 - -
04/30/25 - -
Pre-Tax Margin
10/31/25 - -
07/31/25 - -
04/30/25 - -
Book Value
10/31/25 - -
07/31/25 - 0.48
04/30/25 - 0.46
Inventory Turnover
10/31/25 - -
07/31/25 - -
04/30/25 - -
Debt-to-Equity
10/31/25 - -
07/31/25 - 0.00
04/30/25 - 0.00
Debt-to-Capital
10/31/25 - -
07/31/25 - 0.00
04/30/25 - 0.00
 

Powered by Zacks Investment Research ©